Dr John Patrick Fernald, MD | |
354 Commerce Dr, Beaver, WV 25813-8985 | |
(304) 250-0150 | |
(304) 250-0153 |
Full Name | Dr John Patrick Fernald |
---|---|
Gender | Male |
Speciality | Pediatrics |
Location | 354 Commerce Dr, Beaver, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1730150251 | NPI | - | NPPES |
3810013660 | Medicaid | WV |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 0101234192 (Virginia) | Secondary |
208000000X | Pediatrics | 23655 (West Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Patrick Fernald, MD Po Box 5427, Beckley, WV 25801-7505 Ph: (304) 929-6930 | Dr John Patrick Fernald, MD 354 Commerce Dr, Beaver, WV 25813-8985 Ph: (304) 250-0150 |
News Archive
The person you're speaking with may be looking at you, but are they really paying attention? Or has the person covertly shifted their attention, without moving their eyes? Dr. Brian Corneil, of the Centre for Brain and Mind at The University of Western Ontario in London, Canada has found a way of actually measuring covert attention.
A research group from Germany demonstrated a direct toxic effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on cardiac cells in their paper published on the bioRxiv* preprint server. The finding warrants an in-depth analysis of cardiac tissue in certain coronavirus disease (COVID-19) patients, as well as close monitoring for any direct cardiomyocyte injury.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show.
PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.
› Verified 7 days ago